Building a Global Biotechnology Leader from North Dakota
In 1998, two North Dakota State University (NDSU) students, Michael Chambers and John Ballentyne, set out to solve a highly specific technical challenge: how to reliably produce plasmid DNA, a foundational component for emerging genetic medicines. What began as a small laboratory on NDSU campus has since grown into Aldevron—a global biotechnology manufacturing leader that has helped define both the region’s bioscience industry and the global advancement of genomic medicine.
From its earliest days, Aldevron focused on enabling scientific discovery rather than producing finished therapies. The company manufactures the essential biological materials—plasmid DNA, RNA, proteins, and enzymes—that researchers and bioscience companies rely on to develop vaccines, gene therapies, and other advanced medicines. This positioning has made Aldevron a critical partner across the biotechnology ecosystem, supporting work that addresses diseases such as cancer, rare genetic disorders, and infectious diseases.
Aldevron’s growth helped demonstrate that advanced biomanufacturing could succeed in North Dakota, creating momentum for a broader ecosystem of emerging bioscience companies across the state. As one of the region’s earliest biotechnology companies, Aldevron demonstrated that complex, highly regulated biomanufacturing could successfully take root in Fargo. Its success helped anchor a broader cluster of life sciences activity, attracting talent, investment, and additional companies to the region.
The company’s trajectory also underscores the strength of North Dakota’s innovation environment. Proximity to NDSU, access to highly trained scientific talent, and a collaborative, business-friendly climate enabled Aldevron to scale while remaining headquartered in Fargo. These conditions allowed the company to grow from a startup into a global enterprise, while continuing to invest locally in advanced manufacturing capacity and high-skilled jobs.
Aldevron’s impact extends far beyond regional economic development. The company has played a role in some of the most significant milestones in modern medicine, including supplying critical materials used in mRNA vaccine development and supporting advancements in gene editing therapies. Notably, Aldevron contributed to the manufacture of the world’s first personalized CRISPR-based therapy, highlighting its ability to help translate cutting-edge science into real-world treatments.
In 2021, Aldevron’s acquisition by Danaher Corporation (NYSE: DHR) further elevated its global profile while reinforcing its long-term commitment to Fargo. Today, the company continues to operate as a key part of Danaher’s life sciences portfolio, expanding its capabilities and reach while maintaining its roots in the region
Perhaps most importantly, Aldevron’s story illustrates a broader truth about biotechnology innovation: breakthroughs do not happen in isolation. They require a network of expertise, infrastructure, and collaboration. By focusing on high-quality manufacturing and regulatory excellence, Aldevron has enabled thousands of scientific programs worldwide and supported over a thousand clinical efforts in advanced therapeutics.
For North Dakota, Aldevron represents more than a successful company. It stands as proof that world-class biotechnology can be built—and sustained—in the Midwest. Its journey continues to inspire entrepreneurs, researchers, and policymakers working to expand the state’s life sciences ecosystem.
As BioTech ND looks to the future, Aldevron’s success provides both a foundation and a model: innovation rooted in strong science, scaled through collaboration, and strengthened by the unique advantages of North Dakota.